These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534 [TBL] [Abstract][Full Text] [Related]
9. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699 [TBL] [Abstract][Full Text] [Related]
10. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870 [TBL] [Abstract][Full Text] [Related]
14. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. Choi SH; Jung SC; Kim KW; Lee JY; Choi Y; Park SH; Kim HS J Neurooncol; 2016 Jun; 128(2):185-94. PubMed ID: 27108275 [TBL] [Abstract][Full Text] [Related]
15. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312 [TBL] [Abstract][Full Text] [Related]
16. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270 [TBL] [Abstract][Full Text] [Related]
17. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI. Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions. Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409 [TBL] [Abstract][Full Text] [Related]
19. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289 [TBL] [Abstract][Full Text] [Related]
20. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas. Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]